| 1. |
- Anthony, Lowell B., et al.
(författare)
-
Long-Term Safety Experience with Telotristat Ethyl Across Five Clinical Studies in Patients with Carcinoid Syndrome
- 2019
-
Ingår i: The Oncologist. - : WILEY. - 1083-7159 .- 1549-490X. ; 24:8, s. E662-E670
-
Tidskriftsartikel (refereegranskat)abstract
- Background Patients with neuroendocrine tumors (NETs) and carcinoid syndrome experience considerable morbidity and mortality; carcinoid syndrome may be associated with shorter survival. Carcinoid syndrome is linked to tumoral secretion of serotonin and other bioactive substances. The subsequent debilitating diarrhea and urgency to defecate pose significant health risks. In previous studies, telotristat ethyl, a tryptophan hydroxylase inhibitor, was effective and well tolerated in treating carcinoid syndrome diarrhea. We present pooled safety data from five clinical trials with telotristat ethyl in patients with carcinoid syndrome. Subjects, Materials, and Methods Adverse events reported during telotristat ethyl treatment were pooled from two phase II and three phase III clinical trials in 239 patients with carcinoid syndrome. Long-term safety of telotristat ethyl and causes of hospitalization and death were reviewed; overall survival was estimated. Results Mean (median; range) duration of exposure and follow-up was 1.3 years (1.1 years; 1 week to 5.7 years), with 309 total patient-years of exposure. Leading causes of hospitalization were gastrointestinal disorders or were related to the underlying tumor and related treatment. Survival estimates at 1, 2, and 3 years were 93%, 88%, and 77%. Nearly all deaths were due to progression or complication of the underlying disease; none were attributable to telotristat ethyl. There was one death in year 4. Conclusion Based on long-term safety data, telotristat ethyl is well tolerated and has a favorable long-term safety profile in patients with carcinoid syndrome. Implications for Practice Carcinoid syndrome can cause persistent diarrhea, even in patients treated with somatostatin analogs. Across five clinical trials in patients with carcinoid syndrome, telotristat ethyl has been well tolerated and efficacious, providing clinicians with a new approach to help control carcinoid syndrome diarrhea, in addition to somatostatin analog therapy. By reducing the stool frequency in patients with carcinoid syndrome whose diarrhea is refractory to anticholinergics, such as loperamide and atropine/diphenoxylate, and somatostatin analog dose escalation, improvement in quality of life becomes an achievable goal.
|
|
| 2. |
- Liu, Runnan, et al.
(författare)
-
Detecting Abrupt Change in Channel Covariance Matrix for MIMO Communication
- 2023
-
Ingår i: IEEE Transactions on Wireless Communications. - : IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC. - 1536-1276 .- 1558-2248. ; 22:11, s. 7834-7847
-
Tidskriftsartikel (refereegranskat)abstract
- The acquisition of the channel covariance matrix is of paramount importance to many strategies in multiple-input-multiple-output (MIMO) communications, such as the minimum mean-square error (MMSE) channel estimation. Therefore, plenty of efficient channel covariance matrix estimation schemes have been proposed in the literature. However, an abrupt change in the channel covariance matrix may happen occasionally in practice due to the change in the scattering environment and the user location. Our paper aims to adopt the classic change detection theory to detect the change in the channel covariance matrix as accurately and quickly as possible such that the new covariance matrix can be re-estimated in time. Specifically, this paper first considers the technique of on-line change detection (also known as quickest/sequential change detection), where we need to detect whether a change in the channel covariance matrix occurs at each channel coherence time interval. Next, because the complexity of detecting the change in a high-dimension covariance matrix at each coherence time interval is too high, we devise a low-complexity off-line strategy in massive MIMO systems, where change detection is merely performed at the last channel coherence time interval of a given time period. Numerical results show that our proposed on-line and off-line schemes can detect the channel covariance change with a small delay and a low false alarm rate. Therefore, our paper theoretically and numerically verifies the feasibility of detecting the channel covariance change accurately and quickly in practice.
|
|
| 3. |
- Xiong, Min, et al.
(författare)
-
Tailoring Phase Purity in the 2D/3D Perovskite Heterostructures Using Lattice Mismatch
- 2022
-
Ingår i: ACS Energy Letters. - : AMER CHEMICAL SOC. - 2380-8195. ; 7:1, s. 550-559
-
Tidskriftsartikel (refereegranskat)abstract
- Although the fabrication of two-dimensional (2D)/three-dimensional (3D) halide perovskite heterostructures has been employed to balance the long-term stability and high efficiency of perovskite solar cells, the formation of metastable quasi-2D perovskites remains the most serious challenge. Here, we demonstrate that large lattice mismatch derived from halide and cation differences between 2D and 3D perovskites are key to avoiding the formation of unintended 2D phases in the preparation of 2D/3D bulk heterostructure because the phase transformation becomes less thermodynamically favorable. Specifically, by employing chloride 2D perovskite (PYA)(2) PbCl4 (PYA = propargylammonium) crystals into a 3D precursor solution, we achieve a phase-pure 2D/3D heterojunction with clean type-I band alignment, which exhibits greatly reduced charge recombination. Furthermore, the incorporation of alkyne perovskites is also shown to suppress iodine diffusion and formation due to their exceptional iodine capture capacity. The resultant 2D/3D heterostructured devices exhibited enhanced efficiencies and stabilities compared with their 3D counterparts.
|
|
